259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis

Background

Borderline ovarian tumor(BOT) is a peculiar type of tumor with a favorable prognosis than the malignant tumors.There remains many gaps in our knowledge of the disease that result in controversies regarding their biology and different therapeutic approaches.The study aimed to evaluate the effect of suigical staging procedures on the prognosis and pregnant outcomes in the patients with BOTs.

Methods

We performed a retrospective analysis involving BOT patients who had underwent surgical staging procedures or not in West China Second University Hospital from January 2008 to January 2015 . The recurrence free survival (RFS)and pregnant outcomes were analysed using Kaplan-Meier method and Cox regression analysis, respectively.

Results

448 patients were included in the study with a median age of 35 years and median follow-up time of 113 months.Firty-two(11.6%)patients experienced relapse with the recurrent interval 80.2 months .Four(0.9%)patients died of the disease.118(26.3%)patients had undergone staging surgery while 330(73.7%) had done not.233 patients with fertility sparing surgery(FSS)attempted to conceive and 92(39.48%) achieved pregnancy.No significant difference of fertility outcomes were observed in the stagingsurgery or not groups(P = 0.691).In univariate analyses,staging surgery was obviously associated with RFS (HR = 2.191 P = 0.005),but was not an independent prognostic factor (p = 0.600) .Furthermore,the multivariate Cox analysis revealed that FIGO advanced stage(≥stage II), positive ascitescytologic washing and laparotomy were independent prognostic factors for RFS in the total population.

Conclusions

The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes.When involved in early-stage (I),laproscope will be further rationally recommended to the patients with FSS than laparotomy.In addition, BOT patients with fertility desiring at advanced stage ,with invasive implants and bilateral tumors should choose FSS carefully.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

West China Second University Hospital,SiChuan Univeristy.

Funding

Has not received any funding.

All authors have declared no conflicts of interest.